Cyprus Country Drug Report 2019

Drug-related infectious diseases

In Cyprus, data on notifications of infectious diseases are provided by the Department of Infectious Diseases and the National Acquired Immunodeficiency Syndrome (AIDS) Programme of the Ministry of Health. Other data on drug-related infectious diseases (DRID) are primarily obtained by monitoring DRID prevalence among patients in drug treatment. The number of people who inject drugs (PWID) with valid test results for DRID remains low. In 2017, only a quarter of those entering drug treatment benefited from hepatitis B virus (HBV) and hepatitis C virus (HCV) testing. No on-site testing is offered in outpatient programmes.

Prevalence of HIV and HCV antibodies among people who inject drugs in Cyprus (%)
  Region HCV HIV
Data from 2017.
National 56.6 2.7 - 4.7
Sub-national : :

In 2017, just over half of those tested were found to be positive for HCV. The prevalence of HBV infection among PWID who were tested in drug treatment centres was below 10 %. The prevalence of human immunodeficiency virus (HIV) infections related to drug injecting is estimated to be low compared with other European countries, with two HIV-positive individuals identified in 2017 among the PWID who were tested.


Cyprus main page

Methodological note: Analysis of trends is based only on those countries providing sufficient data to describe changes over the period specified. The reader should also be aware that monitoring patterns and trends in a hidden and stigmatised behaviour like drug use is both practically and methodologically challenging. For this reason, multiple sources of data are used for the purposes of analysis in this report. Caution is therefore required in interpretation, in particular when countries are compared on any single measure. Detailed information on methodology and caveats and comments on the limitations in the information set available can be found in the EMCDDA Statistical Bulletin.